<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2021.104077</article-id><article-id pub-id-type="publisher-id">TCM-44107</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20210400000_62947222.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  基于分子对接技术的龙血竭中干预糖尿病血管病变活性成分虚拟筛选
  Virtual Screening of Bioactive Components from Draconis Resina for the Treatment of Diabetic Vascular Complications
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>洁慧</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>梁</surname><given-names>清峰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>林</surname><given-names>子湘</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>嘉仪</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>潮</surname><given-names>金鸣</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>林</surname><given-names>伟佳</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>汤</surname><given-names>丹</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>广东药科大学药学院，广东 广州</addr-line></aff><aff id="aff4"><addr-line>广东药科大学中药学院，广东 广州；国家中医药管理局中药数字化质量评价技术重点研究室，广东 广州</addr-line></aff><aff id="aff2"><addr-line>广东药科大学中药学院，广东 广州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>30</day><month>06</month><year>2021</year></pub-date><volume>10</volume><issue>04</issue><fpage>565</fpage><lpage>575</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：本研究基于分子对接的计算机虚拟筛选技术，对龙血竭中干预糖尿病血管病变活性成分进行探究。方法：通过系统检索数据库文献，收集整理龙血竭的化学成分，构建了其特征性化学成分信息库。运用AutoDockTools-1.5.6分子对接软件，以RAGE蛋白为靶点，对龙血竭的有效成分进行了虚拟筛选。结果：从31个龙血竭主要成分中筛选出结合能小于−5.00 kcal/mol的化合物有7个，包括(25R)-diosgenin、dracaenogenins B、10-hydroxy-11-methoxydracaenone、7,4’-dihydroxyflavone、2’-methoxysocotrin-5’-ol、broussin和7,4’-dihydroxy-8-methoxyhomoisoflavane。结论：基于分子对接技术的龙血竭中干预糖尿病血管病变活性成分虚拟筛选，为后续研究龙血竭治疗糖尿病血管病变的药效物质提供依据。
  Objective: To explore the bioactive components from Draconis Resina for the treatment of diabetic vascular complications by virtual screening technology. Methods: By systematically searching the database literature and collecting the chemical constituents of Draconis Resina, the chemical information database of Draconis Resina was constructed. Using AutoDockTools-1.5.6 molecular docking software, the effective components of Draconis Resina targeted RAGE protein were virtually screened. Results: Seven compounds with binding energy less than −5.00 kcal/mol were screened from 31 major components of Draconis Resina, including (25R)-diosgenin, dracaenogenins B, 10-hydroxy-11-methoxydracaenone, 7,4’-dihydroxyflavone, 2’-methoxysocotrin-5’-ol, broussin, and 7,4’-dihydroxy-8-methoxyhomoisoflavane. Conclusion: Virtual screening of bioactive com-ponents of Draconis Resina for the treatment of diabetic vascular complications will provide a basis for the further research on the material basis of Draconis Resina.
 
</p></abstract><kwd-group><kwd>分子对接，虚拟筛选，龙血竭，糖尿病血管病变，活性成分, Molecular Docking</kwd><kwd> Virtual Screening</kwd><kwd> Draconis Resina</kwd><kwd> Diabetic Vascular Complications</kwd><kwd> Bioactive Components</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：本研究基于分子对接的计算机虚拟筛选技术，对龙血竭中干预糖尿病血管病变活性成分进行探究。方法：通过系统检索数据库文献，收集整理龙血竭的化学成分，构建了其特征性化学成分信息库。运用AutoDockTools-1.5.6分子对接软件，以RAGE蛋白为靶点，对龙血竭的有效成分进行了虚拟筛选。结果：从31个龙血竭主要成分中筛选出结合能小于−5.00 kcal/mol的化合物有7个，包括(25R)-diosgenin、dracaenogenins B、10-hydroxy-11-methoxydracaenone、7,4’-dihydroxyflavone、2’-methoxysocotrin-5’-ol、broussin和7,4’-dihydroxy-8-methoxyhomoisoflavane。结论：基于分子对接技术的龙血竭中干预糖尿病血管病变活性成分虚拟筛选，为后续研究龙血竭治疗糖尿病血管病变的药效物质提供依据。</p></sec><sec id="s2"><title>关键词</title><p>分子对接，虚拟筛选，龙血竭，糖尿病血管病变，活性成分</p></sec><sec id="s3"><title>Virtual Screening of Bioactive Components from Draconis Resina for the Treatment of Diabetic Vascular Complications<sup> </sup></title><p>Jeihui Yang<sup>1</sup>, Qingfeng Liang<sup>1</sup>, Zixiang Lin<sup>1</sup>, Jiayi Zhang<sup>1</sup>, Jinming Chao<sup>1</sup>, Weijia Lin<sup>2</sup>, Dan Tang<sup>1,3*</sup></p><p><sup>1</sup>School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou Guangdong</p><p><sup>2</sup>School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou Guangdong</p><p><sup>3</sup>Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of SATCM, Guangzhou Guangdong</p><p><img src="//html.hanspub.org/file/14-2270715x5_hanspub.png?20210723170658097" /></p><p>Received: May 31<sup>st</sup>, 2021; accepted: Jul. 15<sup>th</sup>, 2021; published: Jul. 23<sup>rd</sup>, 2021</p><p><img src="//html.hanspub.org/file/14-2270715x6_hanspub.png?20210723170658097" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the bioactive components from Draconis Resina for the treatment of diabetic vascular complications by virtual screening technology. Methods: By systematically searching the database literature and collecting the chemical constituents of Draconis Resina, the chemical information database of Draconis Resina was constructed. Using AutoDockTools-1.5.6 molecular docking software, the effective components of Draconis Resina targeted RAGE protein were virtually screened. Results: Seven compounds with binding energy less than −5.00 kcal/mol were screened from 31 major components of Draconis Resina, including (25R)-diosgenin, dracaenogenins B, 10-hydroxy-11-methoxydracaenone, 7,4’-dihydroxyflavone, 2’-methoxysocotrin-5’-ol, broussin, and 7,4’-dihydroxy-8-methoxyhomoisoflavane. Conclusion: Virtual screening of bioactive components of Draconis Resina for the treatment of diabetic vascular complications will provide a basis for the further research on the material basis of Draconis Resina.</p><p>Keywords:Molecular Docking, Virtual Screening, Draconis Resina, Diabetic Vascular Complications, Bioactive Components</p><disp-formula id="hanspub.44107-formula10"><graphic xlink:href="//html.hanspub.org/file/14-2270715x7_hanspub.png?20210723170658097"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/14-2270715x8_hanspub.png?20210723170658097" /> <img src="//html.hanspub.org/file/14-2270715x9_hanspub.png?20210723170658097" /></p></sec><sec id="s5"><title>1. 引言</title><p>糖尿病是一种以高血糖为特征的慢性代谢性疾病，它的临床患病率逐年升高，已成为当代社会威胁人类身心健康的重大疾病之一 [<xref ref-type="bibr" rid="hanspub.44107-ref1">1</xref>]。持续的高血糖水平会诱发糖尿病血管病变，进而影响机体的心脏、眼睛、肾脏和神经等的正常功能，是糖尿病患者致残甚至死亡的重要原因 [<xref ref-type="bibr" rid="hanspub.44107-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.44107-ref2">2</xref>]。糖尿病血管病变的演变与长期高糖环境导致的晚期糖基化终末产物(AGEs)不断累积密切相关。葡萄糖非酶糖基化产生的AGEs，通过其细胞膜受体RAGE (Receptor of AGEs)介导，激活一系列信号转导通路，诱发氧化应激、炎症反应等，从而导致血管硬度、厚度和通透性增加，血管基底膜及内皮功能异常和损伤等病理改变 [<xref ref-type="bibr" rid="hanspub.44107-ref3">3</xref>]。因此，RAGE蛋白是导致糖尿病血管病变发生与发展的重要靶点。</p><p>龙血竭(Draconis Resina)为百合科剑叶龙血树Dracaena cochinchinensis (Lour.) S. C. Chen的含脂木材经提取得到的树脂，主要分布于我国的广西和云南，具有活血化瘀、消肿定痛等功效，被誉为“活血圣药” [<xref ref-type="bibr" rid="hanspub.44107-ref4">4</xref>]。现代研究表明，龙血竭具有降糖降脂、抗氧化、抗炎、抗血小板聚集、保护心血管等药理作用，并在临床上以龙血竭胶囊、龙血通络胶囊等多种制剂形式广泛运用于心脑血管疾病，且具有良好疗效 [<xref ref-type="bibr" rid="hanspub.44107-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.44107-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.44107-ref7">7</xref>]。</p><p>分子对接技术是借助计算机来实现药物活性成分的虚拟筛选，它的原理类似于“钥匙”与“锁”，即药物小分子(配体)与蛋白质大分子(受体)的相互作用 [<xref ref-type="bibr" rid="hanspub.44107-ref8">8</xref>]。该技术可从化合物数据库中选择大量的中药化学成分进行生物活性的批量虚拟筛选，大大地减少了传统药理实验的时间和财物的浪费，而且还可以提高先导化合物的发现几率 [<xref ref-type="bibr" rid="hanspub.44107-ref9">9</xref>]。近年来，分子对接技术已经逐渐成为中药活性成分筛选的一项重要手段。本研究运用AutoDockTools-1.5.6分子对接软件，以RAGE蛋白为靶点，对龙血竭中干预糖尿病血管病变的活性成分进行研究，从理论上推测出与其结合较稳定的龙血竭活性成分，为深入研究龙血竭奠定了基础，也为后续研究龙血竭治疗糖尿病血管病变的药效物质提供依据。</p></sec><sec id="s6"><title>2. 材料与方法</title><sec id="s6_1"><title>2.1. 材料</title><p>本研究所涉及的数据库有CNKI (https://cnki.net/)，Pubmed (http://pubmed.cn/)，PubChem (有机小分子生物活性数据库，https://pubchem.ncbi.nlm.nih.gov/)，Protein Data Bank (PDB, http://www1.rcsb.org/)。数据分析与处理软件有ChemDraw Professional 19.0，Chem3D 19.0，AutoDockTools-1.5.6，Pymol。</p></sec><sec id="s6_2"><title>2.2. 方法</title><sec id="s6_2_1"><title>2.2.1. 龙血竭化学成分收集</title><p>首先，通过系统检索CNKI、Pubmed等数据库文献，收集整理龙血竭的化学成分；然后，以化学成分的结构分类和药理活性为依据进行第一次筛选得到龙血竭中的主要特征性化学成分，并从PubChem数据库中获取化学成分的SDF格式，数据库中没有找到的化学成分利用ChemDraw Professional 19.0软件进行结构绘制，保存化学成分的SDF格式；最终，在Chem3D 19.0软件界面进行化合物能量最小化处理，力场选择MM2，获得并保存化学成分最小能量的分子结构Mol2格式。</p></sec><sec id="s6_2_2"><title>2.2.2. 靶点蛋白获取</title><p>从PDB数据库下载RAGE蛋白的3D分子结构，PDB ID为4lp4。采用Pymol软件对其进行分析和预处理，包括删除水分子、移除蛋白质结构中的小分子配体、加氢，并根据活性位点，调整对接盒子大小。</p></sec><sec id="s6_2_3"><title>2.2.3. 龙血竭活性成分与RAGE蛋白进行分子对接</title><p>利用AutoDockTools-1.5.6软件对龙血竭活性成分与靶点RAGE蛋白空间结构的匹配情况进行分子对接，根据结合能的大小进行打分。以结合能小于−5.00 kcal/mol为依据，进行第二次筛选。</p></sec><sec id="s6_2_4"><title>2.2.4. 可视化分析</title><p>将得到的龙血竭活性成分与RAGE蛋白的分子对接结果图导入Pymol软件进行可视化分析。</p></sec></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 龙血竭化学成分收集</title><p>通过文献查阅，并根据化学成分的结构分类和药理活性得到龙血竭中的主要特征性化学成分31个，具体化合物信息见表1。</p></sec><sec id="s7_2"><title>3.2. 分子对接结果</title><p>以31个龙血竭活性成分作为配体，以RAGE蛋白为受体，将龙血竭活性成分空间结构分别与RAGE蛋白空间结构进行分子对接，根据其空间结构匹配程度对活性成分进行打分，选取结合能及构象较好的结果作为分子对接结果。最终，筛选出结合能小于−5.00 kcal/mol的化合物有7个，包括(25R)-diosgenin、dracaenogenins B、10-hydroxy-11-methoxydracaenone、7,4'-dihydroxyflavone、2'-methoxysocotrin-5'-ol、</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Chemical composition information table of Draconis Resin</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >序号</th><th align="center" valign="middle" >英文名</th><th align="center" valign="middle" >中文名</th><th align="center" valign="middle" >分子式</th><th align="center" valign="middle" >结构式</th><th align="center" valign="middle" >文献</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >loureirin A</td><td align="center" valign="middle" >龙血素A</td><td align="center" valign="middle" >C<sub>17</sub>H<sub>18</sub>O<sub>4</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x10_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.44107-ref11">11</xref>]</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >loureirin B</td><td align="center" valign="middle" >龙血素B</td><td align="center" valign="middle" >C<sub>18</sub>H<sub>20</sub>O<sub>5</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x11_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.44107-ref11">11</xref>]</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >loureirin C</td><td align="center" valign="middle" >龙血素C</td><td align="center" valign="middle" >C<sub>16</sub>H<sub>16</sub>O<sub>4</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x12_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.44107-ref12">12</xref>]</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >loureirin D</td><td align="center" valign="middle" >龙血素D</td><td align="center" valign="middle" >C<sub>16</sub>H<sub>16</sub>O<sub>5</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x13_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.44107-ref11">11</xref>]</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >2,4'-dihydroxy-4, 6-dimethoxydihydrochalcone</td><td align="center" valign="middle" >2,4'-二羟基-4, 6-二甲氧基二氢查耳酮</td><td align="center" valign="middle" >C<sub>17</sub>H<sub>18</sub>O<sub>5</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x14_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref4">4</xref>]</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >4,4'-dihydroxy-2, 6-dimethoxydihydrochalcone</td><td align="center" valign="middle" >4,4'-二羟基-2, 6-二甲氧基二氢查耳酮</td><td align="center" valign="middle" >C<sub>17</sub>H<sub>18</sub>O<sub>5</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x15_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.44107-ref12">12</xref>]</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >cambodianol</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >C<sub>18</sub>H<sub>18</sub>O<sub>6</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x16_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref13">13</xref>]</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >cambodianin A</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >C<sub>26</sub>H<sub>26</sub>O<sub>6</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x17_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref13">13</xref>]</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >cambodianin B</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >C<sub>27</sub>H<sub>28</sub>O<sub>7</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x18_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref13">13</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >10</th><th align="center" valign="middle" >resveratrol</th><th align="center" valign="middle" >白藜芦醇</th><th align="center" valign="middle" >C<sub>14</sub>H<sub>12</sub>O<sub>3</sub></th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x19_hanspub.png" xlink:type="simple"/></inline-formula></th><th align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.44107-ref12">12</xref>]</th></tr></thead><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >pterostilbene</td><td align="center" valign="middle" >紫檀茋</td><td align="center" valign="middle" >C<sub>16</sub>H<sub>16</sub>O<sub>3</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x20_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.44107-ref10">10</xref>]</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >3,4'-dihydroxy-5- methoxystilbene</td><td align="center" valign="middle" >3,4'-二羟基-5- 甲氧基二苯乙烯</td><td align="center" valign="middle" >C<sub>15</sub>H<sub>14</sub>O<sub>3</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x21_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.44107-ref12">12</xref>]</td></tr><tr><td align="center" valign="middle" >13</td><td align="center" valign="middle" >10-hydroxy-11- methoxydracaenone</td><td align="center" valign="middle" >10-羟基-11- 甲氧基龙血树酮</td><td align="center" valign="middle" >C<sub>17</sub>H<sub>16</sub>O<sub>4</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x22_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.44107-ref14">14</xref>]</td></tr><tr><td align="center" valign="middle" >14</td><td align="center" valign="middle" >7,4'-dihydroxy-5- methoxyhomoisoflavanone</td><td align="center" valign="middle" >7,4'-二羟基-5- 甲氧基高异黄烷酮</td><td align="center" valign="middle" >C<sub>17</sub>H<sub>16</sub>O<sub>5</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x23_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.44107-ref12">12</xref>]</td></tr><tr><td align="center" valign="middle" >15</td><td align="center" valign="middle" >5,7,4'- trihydroxylhomoisoflavanone</td><td align="center" valign="middle" >5,7,4'- 三羟基高异黄烷酮</td><td align="center" valign="middle" >C<sub>16</sub>H<sub>14</sub>O<sub>5</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x24_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref4">4</xref>]</td></tr><tr><td align="center" valign="middle" >16</td><td align="center" valign="middle" >7,4'-dihydroxy-8- methoxyhomoisoflavanone</td><td align="center" valign="middle" >7,4'-二羟基-8- 甲氧基高异黄烷酮</td><td align="center" valign="middle" >C<sub>17</sub>H<sub>16</sub>O<sub>5</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x25_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref4">4</xref>]</td></tr><tr><td align="center" valign="middle" >17</td><td align="center" valign="middle" >7,4'-dihydroxy-8- methoxyhomoisoflavane</td><td align="center" valign="middle" >7,4’-二羟基-8- 甲氧基高异黄烷</td><td align="center" valign="middle" >C<sub>17</sub>H<sub>18</sub>O<sub>4</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x26_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref4">4</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="1_3"><table><tbody><thead><tr><th align="center" valign="middle" >18</th><th align="center" valign="middle" >7,4'-dihydroxyhomoisoflavane</th><th align="center" valign="middle" >7,4'-二羟基高异黄烷</th><th align="center" valign="middle" >C<sub>16</sub>H<sub>16</sub>O<sub>3</sub></th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x27_hanspub.png" xlink:type="simple"/></inline-formula></th><th align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.44107-ref10">10</xref>]</th></tr></thead><tr><td align="center" valign="middle" >19</td><td align="center" valign="middle" >7,4'-dihydroxy-5- methoxyhomoisoflavane</td><td align="center" valign="middle" >7,4'-二羟基-5- 甲氧基高异黄烷</td><td align="center" valign="middle" >C<sub>17</sub>H<sub>18</sub>O<sub>4</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x28_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref4">4</xref>]</td></tr><tr><td align="center" valign="middle" >20</td><td align="center" valign="middle" >7,4'-dihydroxyflavone</td><td align="center" valign="middle" >7,4'-二羟基黄酮</td><td align="center" valign="middle" >C<sub>15</sub>H<sub>1</sub>0O<sub>4</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x29_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.44107-ref12">12</xref>]</td></tr><tr><td align="center" valign="middle" >21</td><td align="center" valign="middle" >liquiritigenin</td><td align="center" valign="middle" >甘草素</td><td align="center" valign="middle" >C<sub>15</sub>H<sub>12</sub>O<sub>4</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x30_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.44107-ref15">15</xref>]</td></tr><tr><td align="center" valign="middle" >22</td><td align="center" valign="middle" >broussin</td><td align="center" valign="middle" >构树素</td><td align="center" valign="middle" >C<sub>16</sub>H<sub>16</sub>O<sub>3</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x31_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.44107-ref16">16</xref>]</td></tr><tr><td align="center" valign="middle" >23</td><td align="center" valign="middle" >cochinchinenin A</td><td align="center" valign="middle" >剑叶龙血素A</td><td align="center" valign="middle" >C<sub>17</sub>H<sub>18</sub>O<sub>4</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x32_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref10">10</xref>]</td></tr><tr><td align="center" valign="middle" >24</td><td align="center" valign="middle" >cochinchinenin B</td><td align="center" valign="middle" >剑叶龙血素B</td><td align="center" valign="middle" >C<sub>33</sub>H<sub>34</sub>O<sub>7</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x33_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref4">4</xref>]</td></tr><tr><td align="center" valign="middle" >25</td><td align="center" valign="middle" >cochinchinenin C</td><td align="center" valign="middle" >剑叶龙血素 C</td><td align="center" valign="middle" >C<sub>33</sub>H<sub>34</sub>O<sub>7</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x34_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref16">16</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="1_4"><table><tbody><thead><tr><th align="center" valign="middle" >26</th><th align="center" valign="middle" >cinnabarone</th><th align="center" valign="middle" ></th><th align="center" valign="middle" >C<sub>32</sub>H<sub>32</sub>O<sub>7</sub></th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x35_hanspub.png" xlink:type="simple"/></inline-formula></th><th align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref4">4</xref>]</th></tr></thead><tr><td align="center" valign="middle" >27</td><td align="center" valign="middle" >2'-methoxysocotrin-5'-ol</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >C<sub>32</sub>H<sub>32</sub>O<sub>7</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x36_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref17">17</xref>]</td></tr><tr><td align="center" valign="middle" >28</td><td align="center" valign="middle" >(2R)-8-methylsocotrin-4'-ol</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >C<sub>32</sub>H<sub>32</sub>O<sub>6</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x37_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref13">13</xref>]</td></tr><tr><td align="center" valign="middle" >29</td><td align="center" valign="middle" >homoisosocotrin-4ʹ-ol</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >C<sub>32</sub>H<sub>32</sub>O<sub>6</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x38_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref13">13</xref>]</td></tr><tr><td align="center" valign="middle" >30</td><td align="center" valign="middle" >dracaenogenins B</td><td align="center" valign="middle" >龙血竭红素B</td><td align="center" valign="middle" >C<sub>27</sub>H<sub>42</sub>O<sub>6</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x39_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.44107-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.44107-ref18">18</xref>]</td></tr><tr><td align="center" valign="middle" >31</td><td align="center" valign="middle" >(25R)-diosgenin</td><td align="center" valign="middle" >(25R)-薯蓣皂苷元</td><td align="center" valign="middle" >C<sub>27</sub>H<sub>42</sub>O<sub>3</sub></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/14-2270715x40_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="hanspub.44107-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.44107-ref12">12</xref>]</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 龙血竭化学成分信息表</p><p>broussin和7,4'-dihydroxy-8-methoxyhomoisoflavane。其中，(25R)-diosgenin、dracaenogenins B和10-hydroxy- 11-methoxydracaenone的结合能小于-6.00 kcal/mol，对接结果见表2。</p></sec><sec id="s7_3"><title>3.3. 可视化分析</title><p>结合能反应受体与配体之间相互结合的可能性，结合能越低表示受体与配体之间亲和力越高，构象也就越稳定，说明两个分子在自然状态下相互结合而释放出来的能量越低，即更容易相互结合 [<xref ref-type="bibr" rid="hanspub.44107-ref18">18</xref>]。本研究选择了亲和力较好的dracaenogenins B这一特征性潜在活性成分进行可视化分析。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Molecular docking results between bioactive components of Draconis Resina and RAGE protei</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >序号</th><th align="center" valign="middle" >化合物</th><th align="center" valign="middle" >靶点名称</th><th align="center" valign="middle" >PDB ID</th><th align="center" valign="middle" >结合能(kcal/mol)</th></tr></thead><tr><td align="center" valign="middle" >31</td><td align="center" valign="middle" >(25R)-diosgenin</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−7.90</td></tr><tr><td align="center" valign="middle" >30</td><td align="center" valign="middle" >dracaenogenins B</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−6.88</td></tr><tr><td align="center" valign="middle" >13</td><td align="center" valign="middle" >10-hydroxy-11-methoxydracaenone</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−6.12</td></tr><tr><td align="center" valign="middle" >20</td><td align="center" valign="middle" >7,4'-dihydroxyflavone</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−5.34</td></tr><tr><td align="center" valign="middle" >27</td><td align="center" valign="middle" >2'-methoxysocotrin-5'-ol</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−5.29</td></tr><tr><td align="center" valign="middle" >22</td><td align="center" valign="middle" >broussin</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−5.02</td></tr><tr><td align="center" valign="middle" >17</td><td align="center" valign="middle" >7,4'-dihydroxy-8-methoxyhomoisoflavane</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−5.01</td></tr><tr><td align="center" valign="middle" >18</td><td align="center" valign="middle" >7,4'-dihydroxyhomoisoflavane</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−4.87</td></tr><tr><td align="center" valign="middle" >19</td><td align="center" valign="middle" >7,4'-dihydroxy-5-methoxyhomoisoflavane</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−4.87</td></tr><tr><td align="center" valign="middle" >14</td><td align="center" valign="middle" >7,4'-dihydroxy-5-methoxyhomoisoflavanone</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−4.79</td></tr><tr><td align="center" valign="middle" >21</td><td align="center" valign="middle" >liquiritigenin</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−4.78</td></tr><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >pterostilbene</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−4.60</td></tr><tr><td align="center" valign="middle" >29</td><td align="center" valign="middle" >homoisosocotrin-4ʹ-ol</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−4.59</td></tr><tr><td align="center" valign="middle" >15</td><td align="center" valign="middle" >5,7,4'-trihydroxylhomoisoflavanone</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−4.42</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >loureirin B</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−4.31</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >resveratrol</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−4.30</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >3,4'-dihydroxy-5-methoxystilbene</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−4.27</td></tr><tr><td align="center" valign="middle" >16</td><td align="center" valign="middle" >7,4'-dihydroxy-8-methoxyhomoisoflavanone</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−4.20</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >cambodianol</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−4.17</td></tr><tr><td align="center" valign="middle" >28</td><td align="center" valign="middle" >(2R)-8-methylsocotrin-4'-ol</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−4.07</td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >loureirin A</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−3.97</td></tr><tr><td align="center" valign="middle" >23</td><td align="center" valign="middle" >cochinchinenin A</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−3.96</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >loureirin C</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−3.86</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >cambodianin A</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−3.75</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >4,4' -dihydroxy-2, 6-dimethoxydihydrochalcone</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−3.65</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >loureirin D</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−3.34</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >2,4'-dihydroxy-4,6-dimethoxydihydrochalcone</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−3.32</td></tr><tr><td align="center" valign="middle" >24</td><td align="center" valign="middle" >cochinchinenin B</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−3.10</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >cambodianin B</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−2.81</td></tr><tr><td align="center" valign="middle" >25</td><td align="center" valign="middle" >cochinchinenin C</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−2.20</td></tr><tr><td align="center" valign="middle" >26</td><td align="center" valign="middle" >cinnabarone</td><td align="center" valign="middle" >RAGE</td><td align="center" valign="middle" >4lp4</td><td align="center" valign="middle" >−1.88</td></tr></tbody></table></table-wrap><p>表2. 龙血竭活性成分与RAGE蛋白的分子对接结果</p><p>以dracaenogenins B与RAGE蛋白分子对接结果为例进行可视化分析，见图1：配体分子dracaenogenins B被受体中的氨基酸残基Thr27(A)、Ala28(A)、Arg29(A)、Glu32(A)、Glu32(B)、Pro33(A)、Pro33(B)、Leu34(B)、Val35(A)、Val35(B)包围。其中，受体中的疏水性残基Thr27(A)、Ala28(A)、Arg29(A)、Glu32(B)、Pro33(B)、Leu34(B)、Val35(A)、Val35(B)，可与配体疏水环形成较强的堆积作用，在dracaenogenins B与RAGE的相互作用中起着至关重要的作用；受体中的亲水性残基Glu32(A)、Pro33(A)与配体形成氢键相互作用，氢键的存在降低了RAGE的亲水性，增加了RAGE的疏水性，有利于提高复合物的的稳定性。图1(d)中虚线为氢键，数值为键长。氨基酸残基Pro33(A)与配体形成氢键的键长为2.63，氨基酸残基Glu32(A)与配体形成氢键的键长分别为2.92和2.80。</p><p>图1. 通过分子对接推测dracaenogenins B-RAGE的最佳构象示意图。(a) Dracaenogenins B-RAGE复合物的最小能量构象；(b) Dracaenogenins B周围RAGE的氨基酸残基；(c) Dracaenogenins B与RAGE的最佳结合位置；(d) Dracaenogenins B与RAGE特定氨基酸残基的相互作用(绿色虚线为氢键，辐射状弧形为疏水作用力。)</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>由于中药化学成分复杂多样，我们用传统的筛选方法需要消耗大量的人力与物力才能从这些化学成分中筛选出具有治疗糖尿病血管病变的活性成分。因此，分子对接虚拟筛选技术在分析中药的活性成分方面就显示出其独特的优势。本研究运用AutoDockTools-1.5.6分子对接软件，以RAGE蛋白为靶点，对龙血竭中的31个主要特征性活性成分采用AutoDockTools-1.5.6软件进行了分子对接，对接结果显示，中药龙血竭中(25R)-diosgenin、dracaenogenins B、10-hydroxy-11-methoxydracaenone、7,4'-dihydroxyflavone、2'-methoxysocotrin-5'-ol、broussin和7,4'-dihydroxy-8-methoxyhomoisoflavane对RAGE蛋白均有较好的亲和力。已有文献报道，diosgenin对STZ诱导的糖尿病大鼠糖代谢的关键酶活性和糖原含量具有调节作用 [<xref ref-type="bibr" rid="hanspub.44107-ref19">19</xref>]；10-hydroxy-11-methoxydracaenone对LPS诱导的BV-2细胞释放NO有抑制作用从而表现出抗炎活性，对缓解缺血性脑中风有一定的疗效 [<xref ref-type="bibr" rid="hanspub.44107-ref20">20</xref>]；7,4'-dihydroxyflavone具有抗血小板凝集活性及对脐静脉上皮细胞的氧化损伤有明显的保护作用 [<xref ref-type="bibr" rid="hanspub.44107-ref21">21</xref>]；7,4'-dihydroxy-8-methoxyhomoisoflavane因具有明显的DPPH自由基清除能力而表现出抗氧化活性 [<xref ref-type="bibr" rid="hanspub.44107-ref22">22</xref>]。</p><p>Dracaenogenins B是2005年首次从龙血竭中分离得到的一个甾醇类特征性成分 [<xref ref-type="bibr" rid="hanspub.44107-ref17">17</xref>]，本研究中分子对接结果显示dracaenogenins B对糖尿病血管病变靶点RAGE的结合力较强(−6.88 kcal/mol)。因此本研究选择了亲和力较好的dracaenogenins B这一特征性潜在活性成分进行可视化分析，旨在通过dracaenogenins B与RAGE蛋白的相互作用模式推测药物小分子是如何作用于RAGE蛋白而达到干预糖尿病血管病变的效果的。从图1我们可以发现，药物小分子(dracaenogenins B)进入RAGE蛋白活性“口袋”，被RAGE蛋白中的氨基酸残基包围并发生较强的结合。相对于其他分子(如AGEs)而言，这些活性药物小分子更容易进入RAGE蛋白活性“口袋”，在与AGEs竞争REGE受体蛋白时有着较好的竞争优势，进一步抑制AGEs与细胞膜中REGE蛋白的正常结合，形成空间位阻效应，达到干预糖尿病血管病变的效果。</p><p>本研究从理论上推测出与RAGE蛋白结合较稳定的龙血竭活性成分，为深入研究龙血竭奠定了基础，也为后续研究龙血竭治疗糖尿病血管病变的药效物质提供依据。但是，虚拟筛选的结果仅仅是在理论水平上推测出的，因此这些化合物治疗糖尿病血管病变的药理活性仍有待于进一步的药理实验验证。</p></sec><sec id="s9"><title>基金项目</title><p>广东省自然科学基金面上项目(2020A1515011515)；广东省大学生创新创业训练计划项目 (S202010573041)。</p></sec><sec id="s10"><title>文章引用</title><p>杨洁慧,梁清峰,林子湘,张嘉仪,潮金鸣,林伟佳,汤 丹. 基于分子对接技术的龙血竭中干预糖尿病血管病变活性成分虚拟筛选 Virtual Screening of Bioactive Components from Draconis Resina for the Treatment of Diabetic Vascular Complications[J]. 中医学, 2021, 10(04): 565-575. https://doi.org/10.12677/TCM.2021.104077</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44107-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">何丹丹, 郑毅, 陈闯, 陈建超, 孙铁民. 治疗糖尿病并发症的药物研究进展[J]. 中南药学, 2017, 15(6): 714-721.</mixed-citation></ref><ref id="hanspub.44107-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, Y., Ley, S.H. and Hu, F.B. (2018) Global Aetiology and Epidemiology of Type 2 Diabetes Mellitus and Its Complications. Nature Reviews Endocrinology, 14, 88-98. &lt;br&gt;https://doi.org /10.1038/nrendo.2017.151</mixed-citation></ref><ref id="hanspub.44107-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">郑晓茂, 茹琴, 陈琳. 晚期糖基化终产物对糖尿病及其并发症的影响和干预的研究进展[J]. 重庆医学, 2019, 48(13): 2292-2296.</mixed-citation></ref><ref id="hanspub.44107-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">汤丹, 肖伟, 钱正明, 曹东敏, 黄广枭, 罗家敏, 等. 活细胞固相色谱法联合高分辨质谱快速筛选龙血竭中镇痛活性成分[J]. 中草药, 2019, 50(11): 2539-2544.</mixed-citation></ref><ref id="hanspub.44107-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">杨敏, 杨瑞, 覃彬华, 余惠凡. 民族药龙血竭研究进展[J]. 海峡药学, 2019, 31(11): 49-52.</mixed-citation></ref><ref id="hanspub.44107-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">陈福锋, 郑亚男, 杜文杰, 梅之南. 龙血竭胶囊抗慢性血瘀证作用的研究[J]. 药物评价研究, 2015, 38(3): 274-278.</mixed-citation></ref><ref id="hanspub.44107-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">朱永林. 龙血通络胶囊联合长春西汀治疗血栓性脑梗死恢复期的疗效观察[J]. 现代药物与临床, 2020, 35(3): 469-472.</mixed-citation></ref><ref id="hanspub.44107-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">冯彩琴, 骆亚莉, 刘永琦, 靳晓杰, 石丹枫, 朱永昌, 等. 基于IL-6R运用分子对接筛选红芪防护BMSCs的活性成分[J]. 重庆医科大学学报, 2019, 44(7): 867-871.</mixed-citation></ref><ref id="hanspub.44107-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">刘芳, 戴荣继, 邓玉林, 刘秀洁, 吕芳. 龙血竭总酚活血化瘀活性成分的虚拟筛选及初步活性研究[J]. 北京理工大学学报, 2015, 35(2): 218-220.</mixed-citation></ref><ref id="hanspub.44107-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">龚韦凡. 龙血竭药材质量标准及镇痛活性的研究[D]: [硕士学位论文]. 武汉: 中南民族大学, 2018.</mixed-citation></ref><ref id="hanspub.44107-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">郑庆安, 王东, 陈江韬, 张颖君, 杨崇仁. 龙血竭化学成分研究[C]//中国民族医药学会, 等. 2005国际傣医药学术会议论文集. 呼和浩特: 《中国民族医药杂志》编辑部, 2005: 3.</mixed-citation></ref><ref id="hanspub.44107-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Tang, Y., Su, G., Li, N., Li, W., Chen, G., Chen, R., et al. (2019) Preventive Agents for Neurodegenerative Diseases from Resin of Dracaena cochinchinensis Attenuate LPS-Induced Microglia Over-Activation. Journal of Natural Medicines, 73, 318-330. &lt;br&gt;https://doi.org /10.1007/s11418-018-1266-y</mixed-citation></ref><ref id="hanspub.44107-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">田颖颖, 杨爱琳, 陈孝男, 李嘉琪, 唐雷梦媛, 黄惠铭, 等. 龙血竭抗肿瘤作用研究进展[J]. 中国中药杂志, 2021, 46(8): 2037-2044.</mixed-citation></ref><ref id="hanspub.44107-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Meksuriyen, D., Cordell, G.A., Ruangrungsi, N. and Tantivatana, P. (1987) Traditional Medicinal Plants of Thailand, IX. 10-Hydroxy-11-methoxydracaenone and 7,10-dihydroxy-11-methoxydracaenone from Dracaena Loureiri. Journal of Natural Products, 50, 1118-1125. &lt;br&gt;https://doi.org /10.1021/np50054a018</mixed-citation></ref><ref id="hanspub.44107-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">苏小琴, 李曼曼, 顾宇凡, 孙晶, 张静, 黄正, 等. 龙血竭酚类成分研究[J]. 中草药, 2014, 45(11): 1511-1514.</mixed-citation></ref><ref id="hanspub.44107-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">林忆龙, 文亦磊, 黄洪, 等. 龙血竭化学成分及药理作用研究进展[J]. 中国民族民间医药, 2020, 29(6): 50-55.</mixed-citation></ref><ref id="hanspub.44107-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, Q.A., Li, H.Z., Zhang, Y.J. and Yang, C.-R. (2006) Dracaenogenins A and B, New Spirostanols from the Red Resin of Dracaena cochinchinensis. Steroids, 71, 160-164. &lt;br&gt;https://doi.org /10.1016/j.steroids.2005.09.007</mixed-citation></ref><ref id="hanspub.44107-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">盛望, 王瑾茜, 殷淑婷, 李旭华, 胡国恒, 谢丽华. 基于网络药理学和分子对接技术研究人参皂苷Rg1治疗阿尔茨海默病的分子生物学机制[J]. 中医药学报, 2020, 48(12): 54-60.</mixed-citation></ref><ref id="hanspub.44107-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Saravanan, G., Ponmurugan, P., Deepa, M.A. and Senthilkumar, B. (2014) Modulatory Effects of Diosgenin on Attenuating the Key Enzymes Activities of Carbohydrate Metabolism and Glycogen Content in Streptozotocin-Induced Diabetic Rats. Canadian Journal of Diabetes, 38, 409-414. &lt;br&gt;https://doi.org /10.1016/j.jcjd.2014.02.004</mixed-citation></ref><ref id="hanspub.44107-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">庞道然. 龙血通络胶囊的化学成分研究[D]: [硕士学位论文]. 北京: 北京中医药大学, 2017.</mixed-citation></ref><ref id="hanspub.44107-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">钟蕾. 龙血竭止血活血双向调节作用机制及质量评价研究[D]: [硕士学位论文]. 上海: 第二军医大学, 2004.</mixed-citation></ref><ref id="hanspub.44107-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">王芳芳, 胡琳, 王兴红. 龙血竭主要黄酮类成分及其DPPH自由基清除活性研究[J]. 云南民族大学学报(自然科学版), 2015, 24(3): 189-193.</mixed-citation></ref></ref-list></back></article>